Evidence map›Paper›PMID 40248275›Full record

ArticleBiological psychiatry global open science2025

Peripheral Blood Cytokines as Markers of Longitudinal Change in White Matter Microstructure Following Inpatient Treatment for Opioid Use Disorders.

Eduardo R Butelman, Yuefeng Huang, Sarah G King, Pierre-Olivier Gaudreault, Ahmet O Ceceli, Greg Kronberg, Flurin Cathomas, Panos Roussos, Scott J Russo, Eric L Garland and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Biological psychiatry global open science, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Eduardo R ButelmanNeuropsychoimaging of Addictions and Related Conditions Research Program, Icahn School of Medicine at Mount Sinai, Departments of Psychiatry and Neuroscience, New York, New York.
Yuefeng HuangNeuropsychoimaging of Addictions and Related Conditions Research Program, Icahn School of Medicine at Mount Sinai, Departments of Psychiatry and Neuroscience, New York, New York.
Sarah G KingNeuropsychoimaging of Addictions and Related Conditions Research Program, Icahn School of Medicine at Mount Sinai, Departments of Psychiatry and Neuroscience, New York, New York.
Pierre-Olivier GaudreaultNeuropsychoimaging of Addictions and Related Conditions Research Program, Icahn School of Medicine at Mount Sinai, Departments of Psychiatry and Neuroscience, New York, New York.
Ahmet O CeceliNeuropsychoimaging of Addictions and Related Conditions Research Program, Icahn School of Medicine at Mount Sinai, Departments of Psychiatry and Neuroscience, New York, New York.
Greg KronbergNeuropsychoimaging of Addictions and Related Conditions Research Program, Icahn School of Medicine at Mount Sinai, Departments of Psychiatry and Neuroscience, New York, New York.
Flurin CathomasFriedman Brain Institute, Icahn School of Medicine at Mount Sinai, New York, New York.
Panos RoussosDepartment of Psychiatry, Icahn School of Medicine at Mount Sinai, New York, New York.
Scott J RussoFriedman Brain Institute, Icahn School of Medicine at Mount Sinai, New York, New York.
Eric L GarlandDepartment of Psychiatry, University of California San Diego, La Jolla, California.
Rita Z GoldsteinNeuropsychoimaging of Addictions and Related Conditions Research Program, Icahn School of Medicine at Mount Sinai, Departments of Psychiatry and Neuroscience, New York, New York.
Nelly Alia-KleinNeuropsychoimaging of Addictions and Related Conditions Research Program, Icahn School of Medicine at Mount Sinai, Departments of Psychiatry and Neuroscience, New York, New York.

Funding

Understanding the molecular mechanisms that contribute to neuropsychiatric symptoms in Alzheimer DiseaseR01AG067025 · NIA · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI FINKBEINER, STEVEN M, HAROUTUNIAN, VAHRAM · 2019 to 2023
$11.8M
ROLE OF PERIPHERAL IMMUNE-DERIVED MMP8 IN STRESS SUSCEPTIBILITYR01MH104559 · NIMH · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI SCOTT JAMES RUSSO · 2014 to 2026
$9.2M
Integrative Single Cell isoform and chromatin accessibility Mapping of Chronic Opioid Exposure in Cognitive Brain Areas in HIVU01DA053625 · NIDA · WEILL MEDICAL COLL OF CORNELL UNIV · PI MILNER, TERESA A, NDHLOVU, LISHOMWA C · 2021 to 2025
$4.0M
Atherosclerosis in cocaine addiction: imaging risk with PET/MRR01DA049547 · NIDA · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI Nelly Alia-Klein, Zahi A. Fayad · 2022 to 2026
$3.9M
Neuroimaging response inhibition and salience attribution changes during mindfulness-based treatment of human heroin addictionR01AT010627 · NCCIH · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI GOLDSTEIN, RITA Z · 2019 to 2023
$3.8M
Neural Circuit Mechanisms of Stress-Impaired Social RewardR01MH127820 · NIMH · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI RUSSO, SCOTT JAMES · 2021 to 2025
$3.5M
TRANSCRIPTOME AND EPIGENOME MAPPING IN DOPAMINE NEURONS FROM THE OPIOID EXPOSED HUMAN BRAINR01DA047880 · NIDA · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI AKBARIAN, SCHAHRAM, BANNON, MICHAEL J · 2019 to 2023
$3.4M
NCCIH NIH HHS R01 AT010627NIA NIH HHS R01 AG067025NIDA NIH HHS R01 DA047880NIDA NIH HHS R01 DA049547NIDA NIH HHS U01 DA053625NIMH NIH HHS R01 MH104559NIMH NIH HHS R01 MH127820
6 · The paper itself

Abstract

Background: Opioid use disorder (OUD) causes major public health morbidity and mortality. Although standard-of-care treatment with medications for OUD (MOUDs) is available, there are few biological markers of the clinical process of recovery. Neurobiological aspects of recovery can include normalization of brain white matter (WM) microstructure, which is sensitive to cytokine signaling. Here, we determined whether blood-based cytokines can be markers of change in WM microstructure following MOUD. Methods: Inpatient individuals with heroin use disorder (iHUDs) ( Results: The cytokine biomarker score was negatively correlated with ΔDTI metrics in frontal, frontoparietal, and corticolimbic WM tracts in iHUDs but not in HCs. Also, serum levels of specific cytokines in the cytokine biomarker score, including the interleukin-related oncostatin M (OSM), similarly correlated with ΔDTI metrics in iHUDs but not in HCs. Serum levels of other specific cytokines were negatively correlated with changes in cue-induced craving and arousal in the iHUDs. Conclusions: Specific serum cytokines, studied alone or as a group, may serve as accessible biomarkers of WM microstructure changes and potential recovery in iHUDs undergoing treatment with MOUD.

Indexed as

Blood biomarkersCytokinesDiffusion tensor imagingHeroinOpioid use disorderRecoveryWhite matter microstructure

Identifiers

PMID40248275
PMCPMC12005283

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.